DAX24.423 +1,3%Est505.646 +1,2%MSCI World4.328 +0,1%Top 10 Crypto16,46 +1,0%Nas22.844 +0,4%Bitcoin102.689 +1,7%Euro1,1719 -0,1%Öl64,33 -1,7%Gold3.857 -0,2%

Precigen Aktie

Kaufen

Verkaufen

Precigen Aktien-Sparplan Precigen Aktien-Sparplan

2,84 EUR -0,03 EUR -1,04 %

22:43:30

BMN

3,33 USD -0,01 USD -0,30 %

nachbörslich23:43:30

BTT

Precigen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Bei einem anderen Broker handeln

Smartphone

Marktkap.834,89 Mio. EUR

Div. Rendite0,00%

WKNA2PZG1

ISINUS74017N1054

SymbolPGEN

Precigen Aktien News

Sortieren:Datum Meistgelesen

05.06.23PR NewswirePrecigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

03.06.23PR NewswirePrecigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Meta...

31.05.23PR NewswirePrecigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastati...

10.05.23PR NewswirePrecigen Reports First Quarter 2023 Financial Results and Business Updates

03.05.23PR NewswirePrecigen to Announce First Quarter 2023 Financial Results on May 10th

26.04.23PR NewswirePrecigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting

17.04.23PR NewswirePrecigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

03.04.23PR NewswirePrecigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

29.03.23PR NewswirePrecigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors

28.03.23PR NewswirePrecigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium

06.03.23PR NewswirePrecigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

24.01.23PR NewswirePrecigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papilloma...

12.01.23PR NewswirePrecigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

04.01.23PR NewswirePrecigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Re...

19.12.22PR NewswirePrecigen to Present at the 41st Annual J.P. Morgan Healthcare Conference

13.12.22PR NewswirePrecigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

09.11.22PR NewswirePrecigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

02.11.22PR NewswirePrecigen to Announce Third Quarter 2022 Financial Results on November 9th

Precigen News

Precigen News: auf dieser Seite finden Sie alle Precigen News und Nachrichten zur Precigen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Precigen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Precigen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.